Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

BACKGROUND: Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Riedl, M. A., Aygören‐Pürsün, E., Baker, J., Farkas, H., Anderson, J., Bernstein, J. A., Bouillet, L., Busse, P., Manning, M., Magerl, M., Gompels, M., Huissoon, A. P., Longhurst, H., Lumry, W., Ritchie, B., Shapiro, R., Soteres, D., Banerji, A., Cancian, M., Johnston, D. T., Craig, T. J., Launay, D., Li, H. H., Liebhaber, M., Nickel, T., Offenberger, J., Rae, W., Schrijvers, R., Triggiani, M., Wedner, H. J., Dobo, S., Cornpropst, M., Clemons, D., Fang, L., Collis, P., Sheridan, W. P., Maurer, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175137/
https://www.ncbi.nlm.nih.gov/pubmed/29688579
http://dx.doi.org/10.1111/all.13466

Ejemplares similares

Ejemplares similares